Related Experiment Video
Updated: Jan 30, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple
Judith Del Campo1, Andres Pizzorno2, Sophia Djebali3
1Osivax, 99, rue de Gerland, 69007 Lyon, France.
Abstract:
Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836, a recombinant protein vaccine based on an oligomerized NP, which shows increased uptake by dendritic cells and immunogenicity compared with NP. Intramuscular immunization in mice with OVX836 induced strong NP-specific CD4+ and CD8+ T-cell systemic responses and established CD8+ tissue memory T cells in the lung parenchyma. Strikingly, OVX836 protected mice against viral challenge with three different influenza A subtypes, isolated several decades apart and induced a reduction in viral load. When co-administered with IIV, OVX836 was even more effective in reducing lung viral load.
More Related Videos
Related Concept Videos
Vaccinations
Dose-Response Relationship: Potency and Efficacy
Inflammatory Response I: Vascular and Cellular
Recombinant DNA
Self-Efficacy
Viral Recombination

